On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $322.83, a high estimate of $400.00, and a low estimate of $220.00.

On Tuesday, Wolfe Research adjusted its stance on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), downgrading the company's stock from Peer Perform to Underperform. The research firm's ...

Dozens more are in clinical testing. Yet the field's best-known companies, led by Alnylam Pharmaceuticals, have only taken RNAi so far. Their drugs are still largely focused on disease targets in the ...

AbbVie and Alnylam Pharmaceuticals witnessed comparable market capitalisation growth, with AbbVie reporting 15.2% and Alnylam Pharmaceuticals 14.9% over Q3 2024. AbbVie’s growth was driven by the ...

In the last three months, 24 analysts have published ratings on Alnylam Pharmaceuticals (NASDAQ:ALNY), offering a diverse range of perspectives from bullish to bearish. In the table below ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a report issued on Friday, Benzinga reports.